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The Use of Monoclonal Antibody G250 in the Therapy
of Renal-Cell Carcinoma
E. Oosterwijk, F.M.J. Debruyne, and J.A, Schalken
S INCE KOHLER AND MILSTEIN described
the technique to isolate monoclonal antibod­
ies (MoAbs),1 much effort has been focused to 
isolate MoAbs reactive with tumor antigens for 
diagnostic and therapeutic applications.2'0 Despite 
intense research, the isolation of clinically relevant 
MoAbs has been disappointing. Preferably, such 
MoAbs are reactive with tumor-specific antigens 
(TSA) which should be expressed by all tumor cells 
of a certain tumor type. However, unequivocal 
evidence for unique TSA in human malignancies is 
still lacking. Most human malignancies have weak, 
if any, detectable immunogenic properties, indicat- 
ing that most human cancers either are nonimmu- 
nogenic or mediate strong immunomodulatory ef­
fects. Current MoAbs of interest recognize tumor- 
associated antigens (TAA) which are either 
differentiation antigens (transiently) expressed dur- 
ing organogenesis, or aberrantly expressed anti­
gens, which are (transiently) expressed elsewhere 
in nonrelated normal tissue(s).
Administration of MoAbs that react with an 
antigen present on many normal tissues may result 
in unwanted side effects and diminish the amount 
of MoAb delivered to the tumor, influencing the 
efficacy of MoAb treatment. Therefore, 1) little 
cross-reactivity with nontumorous tissues is prefer­
able; 2) the TA A density on the tumor cells should 
be high to achieve sufficient accumulation of 
MoAb; and 3) all tumor cells must express the 
TAA to enable the MoAb to specifically target to 
all tumor sites, eg, to accomplish visualization of all 
tumor sites or to achieve complete tumor remis­
sion. Unfortunately, for the vast majority of TAA 
that have been defined by anticarcinoma MoAbs, 
these criteria are not met: 1) the TAA is usually 
expressed on more than one type of carcinoma; 2) 
not all tumors within a given tumor type express 
the TAA (intertumor heterogeneity); 3) not all
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cells within a tumor lesion, including métastasés, 
express a particular TAA (intratumor heterogene­
ity); 4) lesions of one patient express a TAA to a 
varying degree; 5) temporal modulation of TAA 
may occur; and 6) TAA expressed on most cells of 
a particular carcinoma are often expressed on some 
normal adult tissues. In general, with higher percent­
age of positive tumor cells and tumors expressing 
the TAA, cross-reactivity with normal tissues in­
creases.
MOABS REACTIVE WITH RENAL-CELL
CARCINOMA
A number of MoAbs reactive with cell surface 
antigens of renal-cell carcinoma (RCC) have been 
identified.7'15 The specificity of the majority of 
RCC-related MoAbs has been established using 
immunohistochemistry. Less is known about their 
targeting abilities and antitumor efficacy. The 
MoAbs can be divided into two groups: 1) MoAbs 
recognizing differentiation antigens,7'14 and 2) 
MoAbs recognizing RCC-TAA aberrantly ex­
pressed in RCC, ie, recognizing an RCC-antigen 
absent from normal kidney.8'10,14,15 Most MoAbs of 
the latter category show very restricted cross­
reactivity with normal tissues as judged using 
immunohistochemistry. It appears that these MoAbs 
identify different RCC-TAA because they display 
different cross-reactivity with normal tissues. In 
view of their restricted cross-reactivity with normal 
tissues in combination with expression of a given 
RCC-TAA in most RCC, these MoAbs are prime 
candidates for clinical investigations.
One of the MoAbs recognizing an aberrantly 
expressed RCC-TAA, MoAb G250, was obtained
after fusion of spleen cells from a mouse immunized 
with fresh RCC homogenates.15 This MoAb identi­
fies an antigen absent from normal kidney and 
other normal tissues examined, with the exception 
of gastric mucosal cells and cells of the larger bile 
ducts. In the initial study, G250 antigen expression 
of 55 RCC was examined: 42 of 47 primary RCC 
showed homogeneous G250 antigen expression 
(89%), four tumors showed heterogeneous G250
antigen expression and only one primary tumor was 
completely devoid of G250 antigen expression. 
More importantly, of eight métastasés examined,
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five showed homogeneous G250 expression (62%), 
two showed heterogeneous U250 expression and 
one metastasis failed to express U250 antigen.b 
With an increased number of RCC tested, no 
difiere nee with respect to the percentage of RCC 
expressing G250 antigen has been observed. In 77 
of 95 (81%) primary RCC cases that were investi­
gated, more than 50% of tumor cells were scored 
positive and in an additional eight patients, primary 
tumor cells also stained, albeit with lower fre­
quency; ie, approximately 90% of primary RCC 
express C250 antigen. For the metastatic lesions, 
G250-positive tumor cells were noticed in 18 of 22 
tumors (82%) examined, with homogeneous stain­
ing in 9 of 17 metastatic RCC examined (53%). in 
general, clear cell RCC tend to show homogenous 
G250 antigen expression, whereas non-clear cell 
RCC show heterogenous G250 expression. In view 
of the restricted cross-reactivity with normal tissues 
and the homogeneous expression in most RCC 
examined, this MoAb seemed useful as a therapeu­
tic and/or radiodiagnostic agent,
EXPERIMENTAL DATA
Tumor Studies
The preferential accumulation of MoAb G250 
was investigated in a RCC xenograft model.16 
BALB/c nu/nu mice were xenogrufted with human 
RCC and/or human noivRCC tumors, and in­
jected with 12^ I-labeled MoAb G250 lgGl, F(ab')2 
or Fab'. Specific MoAb G250 accumulation was 
observed in the RCC tumors for all antibody forms. 
G250-negative tumors did not show any MoAb 
G250 uptake, nor did the G250-positive tumors 
show increased uptake of nonrelevant immuno­
globulin. Higher uptake was generally found with
intact G250 than with G250 F(ab')¿ or Fab'
fragments, most probably because of slower blood 
clearance, leaving the antibody more time to diffuse 
to the tumor cells. The lowest uptake was observed 
for Fab' fragments, related to a short biological 
half-life and lower avidity. Similar studies were 
performed by Chiou et al with MoAb A6H, an 
MoAb that reacts with a normal kidney-difierentia- 
tion antigen.17 For MoAb G250 as well as MoAb 
A6H relatively high tu mor/blood ratios were ob­
served compared with other mouse targeting stud­
ies. This is possibly related to a general increase in 
permeability of the vascular bed in RCC xeno­
grafts.18
In addition to these mouse-targeting studies,
supplementary studies were performed with ex vivo 
perfused tu mor-bearing human kidneys.19 In this 
model system tumor-bearing kidneys are flushed 
with preservation fluid immediately after surgery, 
whereupon the kidneys can be perfused with the 
MoAb of interest. Using this model system, the 
tumor targeting ability of 99mTc-labeled MoAb 
G250 was investigated. yy,nTc MoAb G250 imaging
of tumor-bearing kidneys resulted in clear images of 
RCC, with no MoAb G250 uptake in normal renal 
tissue. Despite the low temperature (0 to 4°C to 
assure appropriate pressures) and the relatively 
short circulation time (16 hours), tumor to kidney 
ratios were approximately 8:1.19 The preferential 
uptake of MoAb G250 in these ex vivo experi­
ments were a clear indication that this MoAb held 
promise for clinical use.
MoAb G250 Mediated Thcraljy
Tumor cells may be lysed by MoAb-directed 
effector cells, so-called antibody-dependent cell- 
mediated cytotoxicity (ADCC). Several cell types 
have been shown to be active in ADCC, including 
macrophages, natural killer (NK) cells, killer (K) 
cells, and neutrophils. Experimental studies have 
highlighted the importance of antibody subclass»20 
and mouse MoAbs of the IgG2a subclass have been 
shown to have the greatest activity in ADCC
a si'* ; 21.22
The antitumor effect of MoAb 0250 alone and
in combination with biological response modifiers 
(BRMs) was tested in a nude mouse model.23 
Because the original MoAb G250 clone produced 
immunoglobulin of lgGl subclass, a poor mediator 
of ADCC, an IgG2a class switch variant of the 
original clone was developed. As a consequence, 
MoAb G250 specificity, idiotype and avidity were 
retained. Mice carrying established subcutaneous 
RCC tumors of approximately 50 mm* were treated 
with different doses. Administration of 100 pug 
MoAb G250 per mouse for 6 weeks with three 
weekly injections resulted in a significant (P < .01) 
inhibition of mean tumor growth to 50% of control 
tumors. Increasing the MoAb G25Ö dose to 500 
fJLg/dose, showed an inhibition of mean tumor 
growth to 35% of controls (P < .0001 versus 
control group). However, this increased tumor 
growth inhibition was not statistically different 
from the 100-|xg dose schedule. No complete 
tumor regression was observed in any of the treated 
animals.
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For this RCC xenograft (NU12), the optimal 
treatment schedule with biological response modifi­
ers had been established in earlier studies.24 BRM 
treatment alone resulted in significant tumor growth 
inhibition, but complete tumor regression was 
never observed, despite the intense treatment sched­
ule. We combined the best BRM treatment, rIFNa 
plus rTNFa, with MoAb G250 treatment to inves- 
tigate whether the efficacy of this combined treat' 
ment was superior to either treatment alone. This 
combination treatment significantly reduced NU12 
tumor growth as compared with MoAb G250 or 
rIFNa/rTNFa alone (P < .0006 versus MoAb 
G250 alone, P < .003 versus rlFNa plus rTNFa). 
In the majority of mice tumors stabilized, and in 
several mice complete tumor regression was ob- 
served. No effects were observed when mice were 
treated with irrelevant IgG or with MoAb G250 
F (ab') 2 fragments, indicating that the effect was 
MoAb G250 specific and Fc-dependent. The Fc- 
dependency also indicated that ADCC was prob' 
ably playing a role in the destruction of tumor cells.
Histochemical examination revealed that MoAb 
G250- or rlFNa/rTNFa-treated tumors were infil­
trated by very few macrophages, if any, similar to 
control tumors in which macrophage infiltrates 
were absent. In contrast, massive macrophage tu­
mor infiltration was observed in MoAb G250/ 
rIFNa/rTNFa-treated tumors. These infiltrates 
seemed to be infiltrating viable tumor nests and 
surrounded large necrotic areas. Most likely, BRM 
treatment leads to activation of mouse NIK cells 
and macrophages, both mediators of ADCC, result­
ing in effective macrophage-mediated ADCC.23
Although these results are encouraging! it re­
mains to be investigated whether unmodified MoAb 
G250 IgG2a will be useful therapeutically. We have 
performed in vitro ADCC experiments using fresh 
isolated human monocytes as effector cells, and 
have not observed any tumor cell lysis. Different 
RCC cell lines were used to circumvent problems 
that may occur because of the use of a lysis - 
resistent cell line, and to assure that antigen densi ty 
(which has been shown to be important in active
ADCC,25) did not play a role. MoAb G250 IgG2a
may not be effectively recognized by these human 
effector cells or, alternatively, these effector cells 
may have to be activated to mediate ADCC or 
G250-antigen density is too low. The latter possibil­
ity seems unlikely in view of the high number of 
antibody binding sites on these RCC cell lines.
9
Enhancement of the ADCC capability of MoAb 
G250 can probably be achieved by chimerization of 
the antibody (chimeric MoAbs consist of mouse Ig 
variable regions grafted onto human Ig constant 
regions). However, preliminary ADCC experi­
ments with chimeric G250 lgGl and purified 
human monocytes as effector cells have been 
unsuccessful. Combining activated human lympho­
cytes with chimeric MoAb G250 may facilitate
ADCC.
CLINICAL EXPERIENCE
Significant clinical experience with radiolabeled 
murine MoAbs that detect TAA has been acquired 
in the last decade.2'6 Radioimmunoscintigraphy 
studies of RCC with MoAbs have been limited, 
generally restricted to animal models.16,17,26'29 Ves- 
sella et al performed an imaging/radiotherapy trial
in RCC patients with MoAb A6H, an MoAb that
recognizes a kidney differentiation antigen.30,31 Posi­
tive images were obtained in 5 of 15 patients 
examined. The low number of positive images was 
attributed to the presence of circulating antigen, 
and the formation of antigen-antibody complexes. 
The number of positive images increased with an 
altered dosing schedule, but the number of imaged 
lesions remained unsatisfactory.
Based on our targeting studies in RCC-bearing 
mice and in ex vivo perfused tumor-bearing kid­
neys, a phase I study with 13iI-labeled MoAb G250 
was performed.32 In this protein dose escalation 
study, the primary study objectives were evaluation 
of the toxicity, pharmacokinetics, and localization 
capabilities of 1311 MoAb G250. More than 90% of 
primary and metastatic disease as demonstrated by 
magnetic resonance imaging (MRI) and computed 
tomography (CT) scans was imaged by ml MoAb 
G250. Metastatic lesions in lymph nodes, bone, and 
lung were visualized. Furthermore, additional meta­
static disease documented at surgery but not de­
tected by MRI and CT scans was visualized. For 
example, radioimmunoscintigraphy with l3lI MoAb 
G250 showed a small hot spot in the liver of one of 
the patients which was not visualized by other 
means. Nine months later, the patient showed
recurrence of RCC in that precise location. 1311
i
MoAb G250 scanning also revealed diffuse meta­
static RCC not recognizable by MRI or CT in a 
polycystic kidney of another patient.
From the ability of MoAb G250 to yield sharp 
images and visualize small tumor lesions it was
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concluded that MoAb G250 has considerable poten- 
tial as an imaging agent. However, not all primary 
or metastatic RCC lesions express G250 antigen, 
and some express it only in a minority of cells. This 
emphasizes the need for additional RCC-specific 
MoAbs because problems of antigen heterogeneity 
have to be overcome for therapeutic efficacy.
The absorbed dose to the tumor delivered by the 
best MoAb/radionuclide combination studies thus 
far has been calculated at 2,000 to 3,000 cGy, while 
maintaining less than grade IV toxic effects.27 
Vaughan et al calculated the minimal requirement 
for effective therapy with 13lI and 90Y-labeled 
MoAbs injected intravenously assuming an avarage 
accumulation of 0.005% of the administered dose/g 
of tumor and a maximum reasonable whole body 
dose of 2 Gy.33,34 These investigators concluded 
that the tumor uptake should be increased by a 
factor 10 for effective therapy, Calculation of the 
maximal fraction of the injected dose 1311 MoAb 
G250 recovered in tumor sites showed that this was 
generally 10 to 100 times greater than previously 
reported accumulation of radiolabeled MoAb in 
solid tumors. The mean accumulation of the admin­
istered dose was also approximately tenfold higher 
than previously reported, fulfilling die require­
ments of Vaughan et al.33,34
Based on these findings, a phase I/II trial with 
escalating doses of 131I labeled to 10 mg of MoAb 
G250 was undertaken in groups of three patients 
with inoperable metastatic RCC.35 Thus far, 21 
patients have been treated. The maximum adminis­
tered dose has been 90 mCi/m2. Targeting of 
radioactivity to all known sites of disease was seen 
in all G250-antigen positive patients (19 of 21). 
Elevation of hepatic enzymes was observed in 18 
patients, starting approximately 10 days after treat­
ment and returning to baseline by 3 weeks. This 
elevation is probably due to MoAb G250 accumula­
tion in the liver. G250 antigen is expressed in the 
larger bile ducts, and examination of liver biopsy 
specimens in the phase I protein dose escalation 
trial revealed MoAb G250 accumulation in bile 
duct epithelium. However, the amount of MoAb 
G250 necessary to saturate the hepatic compart­
ment was minimal, and estimated in the range of 
200 ]xg. Nevertheless, this amount seems to be 
sufficient to induce mild liver toxicity. At the 
75-mCi/m2 dose level, one of six patients had 
reversible grade IV thrombocytopenia, with a nadir 
at 4 weeks. No other major toxicity has been
observed. There have been no major responses, but 
it is encouraging that stable disease was noted in 11 
patients up to 9 months postradioimmunotherapy, 
as these patients with disseminated inoperable 
RCC tend to do very poorly.
CHIMERIZED MoAb G250
Generally, administration of murine MoAbs to 
patients elicits a human antimouse antibody 
(HAMA) response. This HAMA response is often 
directed against the Fc part of the immunoglobulin 
and independent of the amount of MoAb, or 
administration route. In all sera obtained from 
MoAb G250-injected RCC patients, HAMA of 
the IgM and IgG subclasses were detected.32 For 
repeated administration, eg, multiple radioimmuno­
therapy or multiple treatment with naked antibody 
to induce ADCC, HAMA responses need to be 
minimized because circulation HAMA reduces the 
tumor uptake of MoAb at subsequent administra­
tion because of MoAb-HAMA cross-linking. With 
recombinant technology, mouse MoAb variable 
regions can be grafted onto human Ig constant 
regions, and these constructs can be subsequently 
transfected into mammalian cells, which now pro­
duce chimeric immunoglobulin.36'38 Substitution of 
the mouse Fc part by human Fc has the additional 
advantage that all Fc-related effector functions are 
now matching the human effector cells. Principally, 
the use of chimeric IgG should augment ADCC 
mediated tumor cell lysis, and unmodified chimeric 
MoAb might be suitable to destroy (minimal) 
residual disease. Chimerized antibodies are ex­
pected to be less immunogenic in man. We have 
produced chimeric MoAb G250 (lgGl subclass) 
and are currently testing their efficacy in ADCC 
and will start a phase I protein dose escalation trial 
to investigate the pharmacokinetics and targeting 
ability of chimerized MoAb G250.
G250-RELATED ANTI-IDIOTYPE ANTIBODIES
In the preceding sections, the use of MoAb G250 
as a passive immunotherapeutic agent was dis­
cussed. Another strategy is to use MoAbs to induce
active immunization. In 1974^  Jerne proposed that
the immune system is at a steady state by an 
equilibrium of lymphocytic clones bearing comple­
mentary receptors.39 This equilibrium can be dis­
turbed either by a foreign or self-antigen, resulting 
in a response which aims at the restoration of the 
balance. In this response, anti-antibodies (Ab2)
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play a major role. This hypothesis has become 
known as the network theory and has been substan­
tiated by many investigators. The critical feature of 
this theory is that the binding pocket of the 
antibody that determines its specificity elicits anti- 
antibodies. Several so-called idiotypic determinants 
can be present on one immunoglobulin molecule. 
In some cases anti-idiotypic antibodies will mimic 
the original antigen. These so-called internal image 
Ab2 offer promise as “vaccines” to various infec­
tious agents, and they might be used to induce 
immune responses to tumor antigens.40'46 One of 
the advantages of this appealing approach is the 
long-lasting protection that vaccination with TAA- 
mimicking MoAbs might achieve. Principally, the 
requirements of these internal image MoAbs are 
the same as those for MoAbs recognizing TAA that 
might be useful for passive immunotherapy. Cross­
reactivity with normal tissues should be minimal, to 
minimize undesired side effects related to organ 
toxicity elicited by vaccination with internal image 
MoAbs resembling normal differentiation antigens. 
Chattopadhyay et al have demonstrated that vacci­
nation with Ab2 resembling a melanoma-associ­
ated TAA that is expressed on a restricted number 
of normal tissues can induce TAA-specific re­
sponses, indicating that TAA expression on a 
restricted number of tissues does not hamper the 
successful implementation of Ab2 vaccination.47
Considering the restricted expression of G250, 
vaccination with internal image Ab2 resembling 
this RCC-T A A might represent a new therapy for 
RCC patients. Therefore, we have started to isolate
Ab2 bearing the internal image of MoAb G250. Six
MoAbs were isolated after fusion of spleen cells 
from mice immunized with MoAb G250 which 
showed a dose-dependent inhibition of binding of
i25I-MoAb G250 to antigen. Because Abl-Ab2
interactions in close vicinity of Ab 1-antigen inter­
actions will interfere with Ab 1-antigen binding, 
competition for antigen binding was insufficient 
evidence to conclude that true internal image Ab2 
were isolated. To investigate whether these Ab2 
could substitute for the initial G250 antigen, mice 
and rabbits were immunized with the Ab2 to 
monitor for the occurrence of Ab3 resembling 
MoAb G250 (so-called Abl'). Indeed, for all six 
Ab2 Abl' antibodies were detected, showing the 
functional identity of the six MoAbs and G250 
antigen.48
Initially, these six MoAbs were divided into two
immunologically distinct groups, recognizing two 
partly overlapping epitopes.48 However, additional 
fine specificity studies have shown that the six 
internal-image MoAbs can be divided into four 
mutually exclusive groups, evidence that the six 
Ab2s recognize four slightly different idiotopes in 
the Abl binding pocket.49 Because they seem to 
recognize unique epitopes in the MoAb G250 
binding pocket, it implies that not all six internal 
image MoAbs are true representations of G250 
antigen. Consequently, one of the MoAbs may 
show superior antitumor characteristics.
To investigate the antitumor efficacy of immuni­
zation with Ab2, serum of Ab2-immunized mice 
was transferred to nu/nu BALB/c mice challenged 
with human RCC cells. In this Winn-type assay, 
transfer of any Ab3-serum resulted in significant 
tumor growth inhibition (4 weeks; P < .05 versus 
all control groups, 8 weeks; P < .01 versus all 
control groups) and lower tumor take as compared 
with control groups (Table 1). Four weeks after 
tumor challenge, no significant difference between 
Ab3 treatment groups was seen. Small tumors were 
detectable in all Ab3-treated animals. However, 8 
weeks after tumor challenge (3 weeks after cessa­
tion of therapy), remarkable differences between 
the different treatment groups were observed (Fig 
1). All mice treated with Ab3-91 showed complete 
tumor regression. Macroscopically as well as micro­
scopically no tumor remnants could be detected. 
Ab3-31 treatment resulted in tumor regression in 
the majority of animals and tumor stabilization of 
the remaining tumors. Similarly, Ab3-82 treatment 
effected tumor regression in the majority of ani­
mals, with extremely slow growing tumors in the 
remaining animals. After Ab3-71 treatment, slow 
growing tumors were measurable in all animals. 
The doubling time of tumors remaining after Ab3 
treatment was significantly lengthened. Four weeks 
after cessation of therapy the tumors started to 
grow with doubling times comparable to control 
tumors. It is likely that 4 weeks after discontinua­
tion of therapy the circulating levels of Abl' 
antibody and serum factors were depleted and too 
low for continuation of tumor control. Likewise, 
the early growth of the tumors treated with Ab3-91 
can be explained by a dose effect. Because the Abl ' 
titers were moderate, several treatments may be 
necessary to achieve sufficient high levels of Abl' 
for tumor control and regression. Based on these 
results we conclude that NUH-91 immunization
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Table 1. Summary of Representative Protection Experiment With Ab3 Sera
•
Treatment
No. of 
Mice
Tumor Take 
(% ) 4 w 8 w
Tumor Volume (mm3 ± SE) 
4 w 8 w
Ab3-31 5 100 80 9.8 ± 2.5* 11.8 ±5.6+
Ab3-71 5 100 100 10 ± 2.2* 26.7 ± 5.2+
Ab3-82 6 100 66.7 8.1 ± 2.7* 17.9 i  8.7+
Ab3-91 6 100 0 7.7 ± 2.2* 0+
Nontreatment 6 100 100 23.5 ± 4.4 126 ± 16.6
Ab3-MOPC 5 100 100 29 ± 7.5 98.9 ± 12.3
NMS* 5 100 100 31.8 ± 14.4 114 ± 21.0
*P < .05.
tP < .01 compared with last three cases in this list. 
^Abbreviation: NMS, treated with normai mouse serum.
elicits the most powerful antitumor effects, and 
that this Ab2 might be the best candidate for 
clinical trials.
Because the animals were treated with whole 
serum, the antitumor effects can also be explained 
by circulating serum factors, eg, T cell factors and 
cytokines. We and others have shown that combi­
nation therapy with BRMs, which are serum circu­
lating factors, can result in significant tumor growth 
inhibition. Treatment of established RCC xeno­
grafts with interferon-alfa, tumor necrosis factor 
and MoAb G250 resulted in tumor growth inhibi­
tion and tumor regression.23 However, preliminary 
experiments have shown that Ab3 treatment is 
superior to BRM/MoAbG250 treatment. It is there­
fore likely that at least part of the antitumor effects 
are Abl' related. We are currently investigating
the therapeutic efficacy of Ab3 serum in mice with 
established RCC xenografts.
The tumor regression induced by Ab3 serum 
transfer could also be explained by the presence of 
T cell factors such as specific macrophage arming
factor (SMAF) and mast cell T-Cell factor (MTCF).
These factors can, among others, provide antigen- 
specificity to nonspecific cells.50'52 Immunization of 
immune competent mice with any of the six Ab2 
investigated results in profound transferable anti­
gen-specific cell-mediated immunity, with concomi­
tant serum transferable early delayed-type hyper­
sensitivity responses, attributable toT cell factors.53 
Because these factors persist approximately 2 to 16 
days after immunization,50 and animals were treated 
with immune serum harvested 7 days after immuni­
zation, part of the antitumor effects may have been
C Aba -31
Fig I. Individual tumor growth 
curves of RCC challenged mice 
treated with Ab3 sera. BALB/c 
nu/nu mice received s.c. injections 
of 10s SK-RC-52 cells (G250-posi- 
tive human RCC cell line) in the 
right flank, and treatment was 
started. Four groups of mice were 
treated with i.p. injections of NUH» 
Ab3 sera, and three groups served 
as controls: no treatment was given 
(None), mice were treated with 
serum from MOPC21-KLH immu­
nized mice, or mice received nor­
mal mouse serum (not shown). Tu­
mor volumes are expressed as 
mean ±  SE. Figure is representa­
tive for several independently per­
formed experiments.
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elicited by T cell factors. It is likely that similar 
factors, with similar anti tumor efficacy will be 
induced by Ab2 immunization of RCC patients.
FUTURE PROSPECTS
Our future efforts will be directed at investigat­
ing the targeting ability of chimerized MoAb G250. 
We anticipate that chimerization of murine MoAb 
G250 will allow multiple treatments, because hu- 
man antimouse responses are reduced. If that is 
true, multiple treatments with, eg, high-dose l31I- 
labeled chimeric MoAb G250 would become fea- 
sible. Once the targeting ability and pharmacokinet­
ics of chimeric MoAb G250 are known, we intend 
to investigate the radioimmunotherapeutic poten­
tial of high-dose 131I-labeled chimeric MoAb G250.
In addition, chimerization may provide the anti­
body with appropriate effector functions. This will 
enable engagement of human effector cells with 
chimeric MoAb-G250 coated tumor cells, effectuât- 
ing tumor cell lysis.
We will also pursue the possibilities of anti­
idiotype therapy. Much needs to be resolved with 
respect to the identification of the mechanism 
behind the observed antitumor efficacy. Currently 
we are in the process of identifying which effector 
cells are involved in tumor cell elimination, and are 
investigating which factors are of prime importance 
for tumor regression. Regardless of the effector 
mechanism, our observation that Ab2 vaccination 
results in tumor regression is of clinical relevance 
because it seems to indicate that tumor immunity 
can be acquired. Patients at risk for tumor recur­
rence, eg, patients with T3NoMo disease, may 
benefit from adjuvant treatment by Ab2 vaccina­
tion.
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